Global Personalized Cancer Vaccines Market - 2025 -2033
Personalized Cancer Vaccines Market Size
The global personalized cancer vaccines market size reached US$ 11.33 Billion in 2024 from US$ 10.21 Billion in 2023 and is expected to reach US$ 30.12 Billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.
Overview
The personalized cancer vaccines market is revolutionizing global cancer treatment by shifting from one-size-fits-all therapies to customized immunotherapies that target each patient's unique tumor mutations. Powered by mRNA and neoantigen technologies, these vaccines stimulate the immune system to recognize and destroy cancer cells more precisely. This innovation is driving faster clinical responses, reduced side effects, and long-term remission potential, particularly in hard-to-treat cancers like melanoma and pancreatic cancer. As AI streamlines vaccine design, the approach is becoming increasingly scalable and globally accessible.
Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the personalized cancer vaccines market growth
The rising global prevalence of cancer is significantly accelerating the growth of the personalized cancer vaccines market, as healthcare systems increasingly seek more effective, targeted treatment options. For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
This surge is intensifying the demand for therapies that go beyond the limitations of traditional chemotherapy and radiation, which often cause severe side effects and have variable success rates. Personalized cancer vaccines, designed using each patient’s unique tumor mutations (neoantigens), offer a highly targeted immune response that improves treatment precision and lowers toxicity.
Restraints:
A complex and time-intensive development process is hampering the growth of the personalized cancer vaccines market
Unlike traditional 'one-size-fits-all' therapies, personalized cancer vaccines must be custom-designed for each patient, requiring tumor biopsy, genomic sequencing, neoantigen identification, and vaccine formulation, often taking 6 to 12 weeks or more per patient. This prolonged timeline is critical in aggressive cancers like glioblastoma or metastatic melanoma, where rapid treatment is vital.
Additionally, the need for sophisticated bioinformatics, GMP-certified facilities, and highly trained personnel drives up production costs and limits scalability. In clinical trials, these challenges often lead to patient dropouts or delays, affecting trial outcomes and regulatory timelines. Moreover, the regulatory pathway for personalized vaccines is still evolving, as agencies like the FDA must assess safety and efficacy on a patient-specific basis, adding further complexity. Smaller biotech firms, despite innovation, may lack the infrastructure to scale production quickly. As a result, while the science is promising, the operational demands of personalized vaccine development currently limit widespread adoption and slow down market expansion.
Segmentation Analysis
The global personalized cancer vaccines market is segmented based on vaccine type, indication, end-user, and region.
The mRNA-based vaccines segment from the vaccine type is dominating the personalized cancer vaccines market with a 33.05% share in 2024
mRNA-based vaccines have emerged as the dominant segment in the personalized cancer vaccines market due to their flexibility, speed of development, and strong clinical outcomes. Unlike traditional vaccines, mRNA-based approaches allow for the rapid encoding of patient-specific tumor neoantigens, making them ideal for personalized immunotherapy. The success of mRNA platforms during the COVID-19 pandemic validated their safety, scalability, and global manufacturing potential, accelerating their adoption in oncology.
For instance, Moderna and Merck’s mRNA-4157/V940 demonstrated a 44% reduction in the risk of recurrence or death in melanoma patients when combined with Keytruda. Similarly, BioNTech’s BNT122, developed with Genentech, is in advanced trials for solid tumors and pancreatic cancer. These vaccines leverage AI-driven antigen selection and high-speed sequencing, enabling faster turnaround times compared to dendritic cell or peptide-based vaccines.
Moreover, mRNA vaccines can be produced without using live cells or complex purification, simplifying the manufacturing process and reducing costs at scale. As a result, global pharma giants are heavily focusing on personalized mRNA vaccine pipelines, pushing this segment to the forefront. Their proven clinical efficacy, modularity, and commercial scalability make mRNA-based vaccines the leading force in the evolving personalized cancer vaccine landscape.
Geographical Share Analysis
North America is expected to dominate the global personalized cancer vaccines market with a 41.58% in 2024
North America is projected to lead the global personalized cancer vaccines market due to its advanced healthcare infrastructure, strong R&D ecosystem, and early adoption of cutting-edge immunotherapies. The region is driven by high cancer prevalence and favorable regulatory pathways like the FDA’s Breakthrough Therapy Designation granted to Moderna and Merck’s mRNA-4157/V940 vaccine for melanoma.
The U.S. dominates clinical trial activity, hosting the majority of the 80+ ongoing personalized vaccine trials across cancers such as lung, melanoma, and pancreatic. Major players like BioNTech, Moderna, Merck, and Gritstone Bio are headquartered or partnered in the region, accelerating innovation. Moreover, increasing investment in AI-based antigen selection and mRNA manufacturing capabilities positions North America as the frontrunner in commercializing and scaling personalized cancer vaccines globally.
Competitive Landscape
Top companies in the personalized cancer vaccines market include BioNTech SE, Merck & Co., Inc., Moderna, Inc., Gritstone Bio, Transgene, CureVac SE, Nouscom, and Evaxion A/S, among others.
The global personalized cancer vaccines market report delivers a detailed analysis with 56 key tables, more than 62 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global personalized cancer vaccines market size reached US$ 11.33 Billion in 2024 from US$ 10.21 Billion in 2023 and is expected to reach US$ 30.12 Billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.
Overview
The personalized cancer vaccines market is revolutionizing global cancer treatment by shifting from one-size-fits-all therapies to customized immunotherapies that target each patient's unique tumor mutations. Powered by mRNA and neoantigen technologies, these vaccines stimulate the immune system to recognize and destroy cancer cells more precisely. This innovation is driving faster clinical responses, reduced side effects, and long-term remission potential, particularly in hard-to-treat cancers like melanoma and pancreatic cancer. As AI streamlines vaccine design, the approach is becoming increasingly scalable and globally accessible.
Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the personalized cancer vaccines market growth
The rising global prevalence of cancer is significantly accelerating the growth of the personalized cancer vaccines market, as healthcare systems increasingly seek more effective, targeted treatment options. For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
This surge is intensifying the demand for therapies that go beyond the limitations of traditional chemotherapy and radiation, which often cause severe side effects and have variable success rates. Personalized cancer vaccines, designed using each patient’s unique tumor mutations (neoantigens), offer a highly targeted immune response that improves treatment precision and lowers toxicity.
Restraints:
A complex and time-intensive development process is hampering the growth of the personalized cancer vaccines market
Unlike traditional 'one-size-fits-all' therapies, personalized cancer vaccines must be custom-designed for each patient, requiring tumor biopsy, genomic sequencing, neoantigen identification, and vaccine formulation, often taking 6 to 12 weeks or more per patient. This prolonged timeline is critical in aggressive cancers like glioblastoma or metastatic melanoma, where rapid treatment is vital.
Additionally, the need for sophisticated bioinformatics, GMP-certified facilities, and highly trained personnel drives up production costs and limits scalability. In clinical trials, these challenges often lead to patient dropouts or delays, affecting trial outcomes and regulatory timelines. Moreover, the regulatory pathway for personalized vaccines is still evolving, as agencies like the FDA must assess safety and efficacy on a patient-specific basis, adding further complexity. Smaller biotech firms, despite innovation, may lack the infrastructure to scale production quickly. As a result, while the science is promising, the operational demands of personalized vaccine development currently limit widespread adoption and slow down market expansion.
Segmentation Analysis
The global personalized cancer vaccines market is segmented based on vaccine type, indication, end-user, and region.
The mRNA-based vaccines segment from the vaccine type is dominating the personalized cancer vaccines market with a 33.05% share in 2024
mRNA-based vaccines have emerged as the dominant segment in the personalized cancer vaccines market due to their flexibility, speed of development, and strong clinical outcomes. Unlike traditional vaccines, mRNA-based approaches allow for the rapid encoding of patient-specific tumor neoantigens, making them ideal for personalized immunotherapy. The success of mRNA platforms during the COVID-19 pandemic validated their safety, scalability, and global manufacturing potential, accelerating their adoption in oncology.
For instance, Moderna and Merck’s mRNA-4157/V940 demonstrated a 44% reduction in the risk of recurrence or death in melanoma patients when combined with Keytruda. Similarly, BioNTech’s BNT122, developed with Genentech, is in advanced trials for solid tumors and pancreatic cancer. These vaccines leverage AI-driven antigen selection and high-speed sequencing, enabling faster turnaround times compared to dendritic cell or peptide-based vaccines.
Moreover, mRNA vaccines can be produced without using live cells or complex purification, simplifying the manufacturing process and reducing costs at scale. As a result, global pharma giants are heavily focusing on personalized mRNA vaccine pipelines, pushing this segment to the forefront. Their proven clinical efficacy, modularity, and commercial scalability make mRNA-based vaccines the leading force in the evolving personalized cancer vaccine landscape.
Geographical Share Analysis
North America is expected to dominate the global personalized cancer vaccines market with a 41.58% in 2024
North America is projected to lead the global personalized cancer vaccines market due to its advanced healthcare infrastructure, strong R&D ecosystem, and early adoption of cutting-edge immunotherapies. The region is driven by high cancer prevalence and favorable regulatory pathways like the FDA’s Breakthrough Therapy Designation granted to Moderna and Merck’s mRNA-4157/V940 vaccine for melanoma.
The U.S. dominates clinical trial activity, hosting the majority of the 80+ ongoing personalized vaccine trials across cancers such as lung, melanoma, and pancreatic. Major players like BioNTech, Moderna, Merck, and Gritstone Bio are headquartered or partnered in the region, accelerating innovation. Moreover, increasing investment in AI-based antigen selection and mRNA manufacturing capabilities positions North America as the frontrunner in commercializing and scaling personalized cancer vaccines globally.
Competitive Landscape
Top companies in the personalized cancer vaccines market include BioNTech SE, Merck & Co., Inc., Moderna, Inc., Gritstone Bio, Transgene, CureVac SE, Nouscom, and Evaxion A/S, among others.
The global personalized cancer vaccines market report delivers a detailed analysis with 56 key tables, more than 62 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Vaccine Type
2.4. Snippet by Indication
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Neoantigen Targeting for Precision Therapy
3.1.1.2. Rising Prevalence of Cancer
3.1.2. Restraints
3.1.2.1. Complex and Time-Intensive Development Process
3.1.2.2. Lack of Standardized Regulatory Framework
3.1.3. Opportunity
3.1.3.1. mRNA Platform Expansion into Oncology
3.1.3.2. Combination Therapy Potential
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Pipeline Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. PERSONALIZED CANCER VACCINES MARKET, BY VACCINE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
5.1.2. Market Attractiveness Index, By Vaccine Type
5.2. Dendritic Cell Vaccines*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. mRNA-based Vaccines
5.3.1. Introduction
5.3.2. Pipeline Analysis
5.4. DNA-based Vaccines
5.4.1. Introduction
5.4.2. Pipeline Analysis
5.5. Peptide-based Vaccines
5.5.1. Introduction
5.5.2. Pipeline Analysis
5.6. Viral Vector Vaccines
5.6.1. Introduction
5.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.7. Protein-based Vaccines
5.7.1. Introduction
5.7.2. Pipeline Analysis
5.8. Others
6. PERSONALIZED CANCER VACCINES MARKET, BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Melanoma*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Pancreatic Cancer
6.5. Breast Cancer
6.6. Colorectal Cancer
6.7. Glioblastoma
6.8. Prostate Cancer
6.9. Cervical Cancer
6.10. Others
7. PERSONALIZED CANCER VACCINES MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cancer Research Centers
7.4. Biotechnology & Pharma Companies
7.5. Academic Institutions
7.6. Others
8. PERSONALIZED CANCER VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9. INTRODUCTION
9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. BioNTech SE*
12.1.1. Company Overview
12.1.1.1. Product Portfolio
12.1.1.2. Product Description
12.1.1.3. Product Key Performance Indicators (KPIs)
12.1.2. Financial Overview
12.1.2.1. Company Revenue
12.1.2.2. Geographical Revenue Shares
12.1.2.3. Revenue Forecasts
12.1.3. Key Developments
12.1.3.1. Mergers & Acquisitions
12.1.3.2. Key Product Development Activities
12.1.3.3. Regulatory Approvals, etc.
12.1.3.4. SWOT Analysis
12.2. Merck & Co., Inc.
12.3. Moderna, Inc.
12.4. Gritstone Bio
12.5. Transgene
12.6. CureVac SE
12.7. Nouscom
12.8. Evaxion A/S (LIST NOT EXHAUSTIVE )
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Vaccine Type
2.4. Snippet by Indication
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Neoantigen Targeting for Precision Therapy
3.1.1.2. Rising Prevalence of Cancer
3.1.2. Restraints
3.1.2.1. Complex and Time-Intensive Development Process
3.1.2.2. Lack of Standardized Regulatory Framework
3.1.3. Opportunity
3.1.3.1. mRNA Platform Expansion into Oncology
3.1.3.2. Combination Therapy Potential
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Pipeline Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. PERSONALIZED CANCER VACCINES MARKET, BY VACCINE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
5.1.2. Market Attractiveness Index, By Vaccine Type
5.2. Dendritic Cell Vaccines*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. mRNA-based Vaccines
5.3.1. Introduction
5.3.2. Pipeline Analysis
5.4. DNA-based Vaccines
5.4.1. Introduction
5.4.2. Pipeline Analysis
5.5. Peptide-based Vaccines
5.5.1. Introduction
5.5.2. Pipeline Analysis
5.6. Viral Vector Vaccines
5.6.1. Introduction
5.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.7. Protein-based Vaccines
5.7.1. Introduction
5.7.2. Pipeline Analysis
5.8. Others
6. PERSONALIZED CANCER VACCINES MARKET, BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Melanoma*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Pancreatic Cancer
6.5. Breast Cancer
6.6. Colorectal Cancer
6.7. Glioblastoma
6.8. Prostate Cancer
6.9. Cervical Cancer
6.10. Others
7. PERSONALIZED CANCER VACCINES MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cancer Research Centers
7.4. Biotechnology & Pharma Companies
7.5. Academic Institutions
7.6. Others
8. PERSONALIZED CANCER VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9. INTRODUCTION
9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. BioNTech SE*
12.1.1. Company Overview
12.1.1.1. Product Portfolio
12.1.1.2. Product Description
12.1.1.3. Product Key Performance Indicators (KPIs)
12.1.2. Financial Overview
12.1.2.1. Company Revenue
12.1.2.2. Geographical Revenue Shares
12.1.2.3. Revenue Forecasts
12.1.3. Key Developments
12.1.3.1. Mergers & Acquisitions
12.1.3.2. Key Product Development Activities
12.1.3.3. Regulatory Approvals, etc.
12.1.3.4. SWOT Analysis
12.2. Merck & Co., Inc.
12.3. Moderna, Inc.
12.4. Gritstone Bio
12.5. Transgene
12.6. CureVac SE
12.7. Nouscom
12.8. Evaxion A/S (LIST NOT EXHAUSTIVE )
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Personalized Cancer Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Personalized Cancer Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Personalized Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 7 Global Personalized Cancer Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Personalized Cancer Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Personalized Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Personalized Cancer Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 14 North America Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 18 Europe Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 26 South America Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 BioNTech SE: Overview
Table 34 BioNTech SE: Product Portfolio
Table 35 BioNTech SE: Key Developments
Table 36 Merck & Co., Inc.: Overview
Table 37 Merck & Co., Inc.: Product Portfolio
Table 38 Merck & Co., Inc.: Key Developments
Table 39 Moderna, Inc.: Overview
Table 40 Moderna, Inc.: Product Portfolio
Table 41 Moderna, Inc.: Key Developments
Table 42 Gritstone Bio: Overview
Table 43 Gritstone Bio: Product Portfolio
Table 44 Gritstone Bio: Key Developments
Table 45 Transgene: Overview
Table 46 Transgene: Product Portfolio
Table 47 Transgene: Key Developments
Table 48 CureVac SE: Overview
Table 49 CureVac SE: Product Portfolio
Table 50 CureVac SE: Key Developments
Table 51 Nouscom: Overview
Table 52 Nouscom: Product Portfolio
Table 53 Nouscom: Key Developments
Table 54 Evaxion A/S: Overview
Table 55 Evaxion A/S: Product Portfolio
Table 56 Evaxion A/S: Key Developments
Table 1 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Personalized Cancer Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Personalized Cancer Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Personalized Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 7 Global Personalized Cancer Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Personalized Cancer Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Personalized Cancer Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Personalized Cancer Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 14 North America Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 18 Europe Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 26 South America Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Personalized Cancer Vaccines Market Value, By Vaccine Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Personalized Cancer Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Personalized Cancer Vaccines Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Personalized Cancer Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 BioNTech SE: Overview
Table 34 BioNTech SE: Product Portfolio
Table 35 BioNTech SE: Key Developments
Table 36 Merck & Co., Inc.: Overview
Table 37 Merck & Co., Inc.: Product Portfolio
Table 38 Merck & Co., Inc.: Key Developments
Table 39 Moderna, Inc.: Overview
Table 40 Moderna, Inc.: Product Portfolio
Table 41 Moderna, Inc.: Key Developments
Table 42 Gritstone Bio: Overview
Table 43 Gritstone Bio: Product Portfolio
Table 44 Gritstone Bio: Key Developments
Table 45 Transgene: Overview
Table 46 Transgene: Product Portfolio
Table 47 Transgene: Key Developments
Table 48 CureVac SE: Overview
Table 49 CureVac SE: Product Portfolio
Table 50 CureVac SE: Key Developments
Table 51 Nouscom: Overview
Table 52 Nouscom: Product Portfolio
Table 53 Nouscom: Key Developments
Table 54 Evaxion A/S: Overview
Table 55 Evaxion A/S: Product Portfolio
Table 56 Evaxion A/S: Key Developments
LIST OF FIGURES
Figure 1 Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 3 Global Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Personalized Cancer Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Vaccine Type, 2023-2033 (%)
Figure 7 Dendritic Cell Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 8 mRNA-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 9 DNA-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Peptide-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 11 Viral Vector Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 12 Protein-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 15 Melanoma Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16 Lung Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 17 Pancreatic Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 18 Breast Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Colorectal Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Glioblastoma Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Prostate Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 22 Cervical Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 25 Hospitals End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 26 Cancer Research Centers End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 27 Biotechnology & Pharma Companies End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 28 Academic Institutions End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 29 Others End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 30 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 31 North America Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 32 North America Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 33 North America Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 34 North America Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 35 North America Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 38 Europe Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Europe Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Europe Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 41 Asia-Pacific Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 42 Asia-Pacific Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 44 Asia-Pacific Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 45 Asia-Pacific Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 46 South America Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 47 South America Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 48 South America Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 49 South America Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 54 Middle East and Africa Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 55 BioNTech SE: Financials
Figure 56 Merck & Co., Inc.: Financials
Figure 57 Moderna, Inc.: Financials
Figure 58 Gritstone Bio: Financials
Figure 59 Transgene: Financials
Figure 60 CureVac SE: Financials
Figure 61 Nouscom: Financials
Figure 62 Evaxion A/S: Financials
Figure 1 Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 3 Global Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Personalized Cancer Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Vaccine Type, 2023-2033 (%)
Figure 7 Dendritic Cell Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 8 mRNA-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 9 DNA-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Peptide-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 11 Viral Vector Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 12 Protein-based Vaccines Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 15 Melanoma Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16 Lung Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 17 Pancreatic Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 18 Breast Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Colorectal Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Glioblastoma Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Prostate Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 22 Cervical Cancer Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Indication in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 25 Hospitals End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 26 Cancer Research Centers End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 27 Biotechnology & Pharma Companies End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 28 Academic Institutions End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 29 Others End-User in Global Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 30 Global Personalized Cancer Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 31 North America Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 32 North America Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 33 North America Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 34 North America Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 35 North America Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 36 Europe Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 37 Europe Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 38 Europe Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Europe Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Europe Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 41 Asia-Pacific Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 42 Asia-Pacific Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 44 Asia-Pacific Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 45 Asia-Pacific Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 46 South America Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 47 South America Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 48 South America Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 49 South America Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Personalized Cancer Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Personalized Cancer Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Personalized Cancer Vaccines Market Share, By Vaccine Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Personalized Cancer Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 54 Middle East and Africa Personalized Cancer Vaccines Market Share, By End-User, 2024 & 2033 (%)
Figure 55 BioNTech SE: Financials
Figure 56 Merck & Co., Inc.: Financials
Figure 57 Moderna, Inc.: Financials
Figure 58 Gritstone Bio: Financials
Figure 59 Transgene: Financials
Figure 60 CureVac SE: Financials
Figure 61 Nouscom: Financials
Figure 62 Evaxion A/S: Financials
